Therefore, further research is needed to understand the potential mechanisms of SGLT2 inhibitors on bone metabolism, turnover, microarchitecture, and calcium and phosphate homeostasis, as well as the long-term effects of SGLT2 inhibitors on bone health in T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.